Vancomycin-Associated Nephrotoxicity: The Obesity Factor

被引:18
|
作者
Davies, Stephen W. [1 ]
Efird, Jimmy T. [2 ]
Guidry, Christopher A. [1 ]
Dietch, Zachary C. [1 ]
Willis, Rhett N. [1 ]
Shah, Puja M. [1 ]
Hennessy, Sara A. [1 ]
Sawyer, Robert G. [1 ]
机构
[1] Univ Virginia, Sch Med, Dept Gen Surg, Charlottesville, VA 22908 USA
[2] E Carolina Univ, Biostat Unit, Brody Sch Med, Ctr Hlth Dispar, Greenville, NC USA
基金
美国国家卫生研究院;
关键词
RETROSPECTIVE ANALYSIS; IMPACT; PHARMACOKINETICS; DYSLIPIDEMIA; INFECTIONS; OVERWEIGHT; TOXICITY; OUTCOMES; DOSAGE;
D O I
10.1089/sur.2014.198
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Current recommendations suggest that vancomycin dosing utilize actual rather than ideal body weight in obese patients. Thus, obese patients may be at greater risk for nephrotoxicity. The purpose of this study was to compare the incidence of nephrotoxicity in vancomycin-treated obese and lean patients at our institution, where unadjusted, actual body weight-based dosing (capped at 2g per dose twice daily) is used. We expected obese patients to experience a greater incidence of nephrotoxicity than lean patients. Methods: This study examined a retrospective cohort of patients treated with vancomycin for gram-positive or mixed infections in our facility from 2005-2009 who were not receiving hemodialysis at the time of admission. Patients were stratified by body mass index (BMI; obese 30kg/m(2) vs. lean <30kg/m(2)). Relative risk (RR), 95% confidence intervals (CIs), and p values were computed using a generalized estimating equation to accommodate a correlated data structure corresponding to multiple episodes of infection per individual. Multivariable analysis was performed. Results: A total of 530 patients (207 obese; 323 lean) with 1,007 episodes of infection were treated with vancomycin. Patient demographics, co-morbidities, sites of infection, and infecting organisms were similar in the two groups. Female gender (p=0.042), diabetes mellitus (DM) (p=0.018), and hypertension (HTN) (p=0.0009) were more often associated with obesity, whereas allografts (p=0.022) and peripheral vascular disease (p=0.036) were more often present in lean patients. The Acute Physiology and Chronic Health Evaluation II score >21 was the only variable associated with nephrotoxicity (p=0.039). After adjusting for statistically significant variables, obesity was found not to be associated with a greater risk of nephrotoxicity (RR=0.98; 95% CI=0.93-1.04; p=0.59). Conclusion: No difference in nephrotoxicity was observed between lean and obese patients treated with vancomycin at our institution.
引用
收藏
页码:684 / 693
页数:10
相关论文
共 50 条
  • [31] Vancomycin-Associated Uterine Contractions and Bleeding
    Bader, Mazen S.
    Brooks, Annie
    [J]. ANNALS OF PHARMACOTHERAPY, 2010, 44 (03) : 594 - 595
  • [32] Vancomycin-associated nephrotoxicity in noncritically ill patients admitted in a Brazilian public hospital: A prospective cohort study
    Carneiro de Almeida, Claudmeire Dias
    Simoes e Silva, Ana Cristina
    de Queiroz Oliveira, Joao Antonio
    Fonseca Batista, Isabela Soares
    Pereira, Fernando Henrique
    Goncalves, Jose Eduardo
    Nobre, Vandack
    Parreiras Martins, Maria Auxiliadora
    [J]. PLOS ONE, 2019, 14 (09):
  • [33] VANCOMYCIN ASSOCIATED NEPHROTOXICITY
    Gudlawar, Sirisha
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2023, 81 (04) : S2 - S3
  • [34] Probable vancomycin-associated toxic epidermal necrolysis
    Craycraft, ME
    Arunakul, VL
    Humeniuk, JM
    [J]. PHARMACOTHERAPY, 2005, 25 (02): : 308 - 312
  • [35] Noninvasive screening of vancomycin-associated cast nephropathy
    Rafat, Cedric
    Zaworski, Jeremy
    Luque, Yosu
    Daudon, Michel
    Doreille, Alice
    Mesnard, Laurent
    Letavernier, Emmanuel
    [J]. KIDNEY INTERNATIONAL, 2022, 101 (02) : 425 - 425
  • [36] Vancomycin-associated linear IgA bullous dermatosis
    Nousari, HC
    Costarangos, C
    Anhalt, GJ
    [J]. ANNALS OF INTERNAL MEDICINE, 1998, 129 (06) : 507 - 508
  • [37] Vancomycin-Associated Cast Nephropathy: Reality or Fantasy?
    Stokes, Michael B.
    Stevens, Jacob S.
    [J]. KIDNEY360, 2022, 3 (02): : 372 - 375
  • [38] Intravenous Vancomycin Associated With the Development of Nephrotoxicity in Patients With Class III Obesity
    Choi, Yookyung Christy
    Saw, Stephen
    Soliman, Daniel
    Bingham, Angela L.
    Pontiggia, Laura
    Hunter, Krystal
    Chuang, Linda
    Siemianowski, Laura A.
    Ereshefsky, Benjamin
    Hollands, James M.
    [J]. ANNALS OF PHARMACOTHERAPY, 2017, 51 (11) : 937 - 944
  • [39] Vanquishing Vancomycin-Associated Acute Interstitial Nephritis
    Giehl, Nolan M.
    Nobakht, Niloofar
    Zuckerman, Jonathan E.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 781 - 781
  • [40] NIFEDIPINE AND VANCOMYCIN-ASSOCIATED RED MAN SYNDROME
    DALY, BM
    SHARKEY, I
    [J]. DRUG INTELLIGENCE & CLINICAL PHARMACY, 1986, 20 (12): : 986 - 986